eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
 
2/2007
vol. 45
 
Share:
Share:
more
 
 
abstract:

Calcinosis in rheumatic diseases

Anna Rychlewska-Hańczewska
,
Mariusz Puszczewicz

Reumatologia 2007; 45, 2:97-101
Online publish date: 2007/04/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Clacinosis occurs in damaged or devitalized tissues in the presence of normal calcium/phosphorus metabolism. It is often noted in the subcutaneous tissues in the course of connective tissues diseases – primarily systemic lupus erythematosus systemicus, sclerodermia and dermatomyositis – and may involve a relatively localized area or be widespread. The aim of the study was to discuss the classification, pathogenesis, clinical features and treatment of calcinosis in rheumatic diseases. The calcinotic accumulations may lead secondarily to muscle atrophy, join contractures and skin ulceration complicated by recurrent episodes of local inflammation and infection. Warfarin, colchicines, probenecid, bisphosphonates, diltiazem, minocycline, aluminium hydroxide, salicylate, surgical extirpation and carbon dioxide laser therapies have been used in the treatment of calcinosis. However, that kind of medication has not convincingly prevented or reduced calcinosis.
keywords:

calcinosis, lupus erythematosus systemicus, sclerodermia, dermatomyositis







Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe